Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

296 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial.
Blixt L, Wullimann D, Aleman S, Lundin J, Chen P, Gao Y, Cuapio A, Akber M, Lange J, Rivera-Ballesteros O, Buggert M, Ljunggren HG, Hansson L, Österborg A. Blixt L, et al. Among authors: lundin j. Haematologica. 2022 Apr 1;107(4):1000-1003. doi: 10.3324/haematol.2021.280300. Haematologica. 2022. PMID: 35045694 Free PMC article. Clinical Trial. No abstract available.
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.
Winqvist M, Asklid A, Andersson PO, Karlsson K, Karlsson C, Lauri B, Lundin J, Mattsson M, Norin S, Sandstedt A, Hansson L, Österborg A. Winqvist M, et al. Among authors: lundin j. Haematologica. 2016 Dec;101(12):1573-1580. doi: 10.3324/haematol.2016.144576. Epub 2016 May 19. Haematologica. 2016. PMID: 27198718 Free PMC article.
Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints.
Winqvist M, Mozaffari F, Palma M, Eketorp Sylvan S, Hansson L, Mellstedt H, Österborg A, Lundin J. Winqvist M, et al. Among authors: lundin j. Cancer Immunol Immunother. 2017 Jan;66(1):91-102. doi: 10.1007/s00262-016-1922-6. Epub 2016 Nov 4. Cancer Immunol Immunother. 2017. PMID: 27815572 Free PMC article. Clinical Trial.
Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort.
Winqvist M, Andersson PO, Asklid A, Karlsson K, Karlsson C, Lauri B, Lundin J, Mattsson M, Norin S, Sandstedt A, Rosenquist R, Späth F, Hansson L, Österborg A; Swedish CLL Group. Winqvist M, et al. Among authors: lundin j. Haematologica. 2019 May;104(5):e208-e210. doi: 10.3324/haematol.2018.198820. Epub 2018 Dec 4. Haematologica. 2019. PMID: 30514799 Free PMC article. No abstract available.
The biology and treatment of chronic lymphocytic leukemia.
Palma M, Kokhaei P, Lundin J, Choudhury A, Mellstedt H, Osterborg A. Palma M, et al. Among authors: lundin j. Ann Oncol. 2006 Sep;17 Suppl 10:x144-54. doi: 10.1093/annonc/mdl252. Ann Oncol. 2006. PMID: 17018715 Free article. Review. No abstract available.
296 results